Viking Therapeutics (VKTX) Operating Leases (2019 - 2026)

Viking Therapeutics has reported Operating Leases for 7 years, with the latest figure at $3.9 million in Q2 2026.

• Quarterly Operating Leases rose 857.32% year-over-year to $3.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.9 million (up 857.32% YoY) and the FY2024 annual result came in at $630000.0, down 32.69% from the prior year.
• Operating Leases climbed to $3.9 million in Q2 2026 per VKTX's latest filing, from $318000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $3.9 million in Q2 2026 and troughed at $318000.0 in Q3 2025.
• A 5-year average of $1.1 million and a median of $977000.0 in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2025 and 2026: Operating Leases tumbled 57.88% in 2025, then surged 857.32% in 2026.
• Over 5 years, Operating Leases stood at $1.3 million in 2022, then retreated by 25.71% to $936000.0 in 2023, then plunged by 32.69% to $630000.0 in 2024, then sank by 49.52% to $318000.0 in 2025, then soared by 1134.28% to $3.9 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $3.9 million, $318000.0, and $410000.0 for Q2 2026, Q3 2025, and Q2 2025 respectively.